Castle Bio Adds New Outcome Data for Melanoma Assay, Shares Early Info on Skin Disease Test
Source: Genome Web, May 2022
NEW YORK – Castle Biosciences said this week that it is making progress on several research fronts, including building evidence for the survival benefit afforded to patients by its cutaneous melanoma test, DecisionDx-Melanoma.
